Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit
11 févr. 2022 07h30 HE
|
Sensei Biotherapeutics
BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Announces Executive Promotions
06 janv. 2022 08h00 HE
|
Sensei Biotherapeutics
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award
16 déc. 2021 09h01 HE
|
Sensei Biotherapeutics
BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
13 déc. 2021 16h01 HE
|
Sensei Biotherapeutics
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
19 nov. 2021 16h02 HE
|
Sensei Biotherapeutics
BOSTON, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
12 nov. 2021 07h02 HE
|
Sensei Biotherapeutics
V-domain Ig-containing suppressor of T-cell activation (VISTA) is a novel immune checkpoint protein that has been recognized as an important potential immunotherapeutic target Preclinical data...
Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights
09 nov. 2021 08h54 HE
|
Sensei Biotherapeutics
- SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer’s...
Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021
03 nov. 2021 09h01 HE
|
Sensei Biotherapeutics
BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
01 oct. 2021 08h05 HE
|
Sensei Biotherapeutics
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
04 août 2021 07h45 HE
|
Sensei Biotherapeutics
- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model – - Company...